Where Will Gilead Sciences Be in 5 Years?
Five years ago, Gilead Sciences (NASDAQ: GILD) was near its all-time peak. The stock had skyrocketed more than sixfold. Sales were higher than ever thanks to the company's HIV and hepatitis C virus (HCV) franchises. But the good times didn't last very long.
Gilead's revenue, earnings, and share price sank over the following years. There was a game of musical chairs with the company's executive group, as nearly all of the individuals who led Gilead through its heyday were replaced. In retrospect, it's easy to see why the biotech fell from its perch.
While hindsight might be 20/20, looking ahead to Gilead's future certainly is a lot more difficult. Where will Gilead Sciences be in five years? Here's a very tentative prediction.
Source Fool.com
